ADL Amdl,

TUSTIN, Calif., June 21 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that JPI, through its subsidiary JJB, has received initial purchase orders from two of its new distribution partners for approximately $1.3 million. These purchase orders include an order from Anhui Huayuan Medical Co. Ltd., (AHM) a direct subsidiary of China Resources (Holdings) Co., Ltd. This initial order is for approximately $650,000 in products. Next, JPI has also received from Hunan Changsha Double Crane Pharmaceutical Co. Ltd. an initial purchase order for approximately $661,000 in products. JPI is primarily initially selling various Jade products including Domperidon Tablets, Benzoic Acid /Camphor Solutions and Levofloxacin. Mr. Frank Zheng, Managing Director of JPI, stated that "these two initial purchase orders puts JPI on its way to building sales in Southern China and the Shanghai regional markets by as much as (US) $24 million over the next 12 month sales cycle." Mr. Gary Dreher, CEO of AMDL, noted that, "These initial purchase agreements are truly exciting and significantly enhances JPI's ability to grow its sales in these China markets." About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice ('CGMP') standards. About Anhui Medical: AHM was found in 1953, and is one of the largest pharmaceutical distributors in China with products ranging from new medicines, generic medicine and health supplements. AHM was recently acquired by China Resource Holdings Co., which formed one of largest pharmaceutical businesses in China. Currently, AHM has a sales and marketing network that includes more than 4,400 local and provincial based pharmaceutical distributors selling over 25,000 medical products nationwide in China. AHM is ranked as one of the top 3 pharmaceutical distributors in China. In 2006, AHM had sales of approximately US$1.2 billion. In 2003, AHM built the first online pharmacy in China and is currently the largest on-line pharmacy in China. About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul Knopick of AMDL Investor Relations, direct, +1-949-707-5365, voice mail, +1-714-505-4460 Web site: http://www.amdl.com/

Copyright